The role of macrophage activation in the candidacidal activity of liposome-incorporated (L) amphotericin B was investigated. Macrophages treated with L-amphotericin B killed Candida albicans more effectively than did macrophages treated with free (F) amphotericin B. However, macrophages treated with neither F- nor L-amphotericin B killed amphotericin B-resistant Candida tropicalis. In vivo stim...

Although liposomal amphotericin B (AmBisome) is considered as the first-line treatment for New Kala-azar, there is not enough evidence on the dosage formulation in children and its effect on them. Being considered as the safest drug for treatment of Kala-azar, this case of AmBisome-induced avascular necrosis now gives rise to the question; whether it is actually safe enough and if a dosage modi...

Liposomal amphotericin B has a wide array of indications and recent data support the ability to escalate the dose in very serious infection. There is an extensive body of knowledge and history of use (familiarity) regarding the use of liposomal amphotericin B which has been published in the scientific and clinical literature since 1990. The number of publications implies a significant level of ...

DESCRIPTION ABELCET is a sterile, pyrogen-free suspension for intravenous infusion. ABELCET consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine (DMPC) and l-α-dimyristoylphosphatidylglycerol (DMPG), are present in a 7:3 molar ratio. ABELCET is yellow and opaque in appearance, with a pH of 5 7. ...

Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and ...

KEY CLINICAL MESSAGE Successful management of cases with visceral leishmaniasis (VL) and tuberculosis is a challenge for clinicians, because a guideline for that is currently unavailable. We report the first case in Bangladesh who developed VL during her treatment for pulmonary tuberculosis and was treated successfully with multidose liposomal amhptericin B for VL.

are indicated to determine the true incidence of melioidosis in Central America, South America, and the Caribbean. Finally, I must correct some factual inaccuracies. First, the patient originally described by Whitmore and Krishnaswami [7] was 40 years old, not 10 years old as stated by Dorman et al. [1]. Second, the longest incubation period for melioidosis has recently been increased to 29 yea...